Duloxetine RCT on Postop TKA Outcomes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05086393|
Recruitment Status : Recruiting
First Posted : October 20, 2021
Last Update Posted : November 18, 2021
|Condition or disease||Intervention/treatment||Phase|
|Pain, Postoperative Total Knee Arthroplasty||Drug: Duloxetine Drug: Placebos||Phase 4|
Despite advances in surgical techniques and multimodal analgesia, many patients experience severe pain following total knee arthroplasty (TKA). In addition, chronic osteoarthritis, the most common reason patients undergo arthroplasty, predisposes patients to neuropathic pain with an estimated 23% of osteoarthritic patients suffering from neuropathic pain in addition to their nociceptive pain. This process is believed to lower the pain threshold and may lead to central sensitization, a condition defined as "the increase in the excitability and synaptic efficacy of neurons in the central nociceptive pathways that manifests as pain hypersensitivity." Central sensitization is present in 20% to 40% of patients with advanced knee osteoarthritis and believed to predispose them to increased preoperative and postoperative levels of pain.
In previous studies, duloxetine has been shown to reduce postoperative pain and opioid consumption. In a 2019 randomized controlled trial (RCT), Ko et al. reported that 30 milligrams (mg) of duloxetine administered one day prior to surgery and continued for 6 weeks after surgery decreased pain scores in patients with central sensitization who underwent TKA. Duloxetine administered for a shorter duration of time has also shown beneficial results. In their 2010 study, Ho et al. found that although 60 mg of duloxetine administered prior to surgery and on the first postoperative day did not significantly improve postoperative pain scores, it significantly reduced postoperative inpatient morphine requirements following TKA. Similarly, in a 2016, triple-blinded, randomized, placebo-controlled trial, YaDeau et al. found that 60 mg of duloxetine given for 15 days following surgery did not significantly impact pain scores but did significantly reduce opioid consumption in the two weeks following TKA. Although promising, these previous studies are difficult to interpret as they evaluated different patient populations, used different dosages of duloxetine, and administered for different lengths of time.
To our knowledge, all previous prospective, randomized controlled trials have examined only patients undergoing TKA, either focused only on patients with central sensitization or failed to differentiate between patients with and without central sensitization in their study population, or failed to administer duloxetine for the 4-8 week duration that has been traditionally recommended to assess the efficacy of SNRIs for other clinical indications.
The researchers propose to fill this knowledge gap by conducting a study that evaluates TKA patients, includes and differentiates patients with and without central sensitization, and administers duloxetine for the full recommended trial duration.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||504 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage. Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing THA and TKA at Rush University Medical Center.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||This study will be triple-blind, thus, the patients, clinicians, and study members involved will be unaware of patient allocation during this study. After the patient completes his or her Central Sensitization Inventory, a study coordinator will grade the survey to determine if the patient should be allocated to the groups with central sensitization or without. Each patient will receive a study ID based on his or her group (detailed in Section XIV). A computer randomization system will be used to allocate patients to receive either duloxetine or a placebo based on their study ID. Only members of the Rush pharmacy staff will possess the list matching the study ID to the study group assignment, ensuring that the study remains triple-blinded and that study coordinators are unaware of a patient's assignment when he or she picks up the study medication from the pharmacy.|
|Official Title:||A Prospective, Triple-Blind, Randomized Controlled Trial Evaluating Duloxetine on Post-Operative Outcomes Following Primary Total Knee Arthroplasty in Patients With and Without Central Sensitization|
|Actual Study Start Date :||November 1, 2021|
|Estimated Primary Completion Date :||January 1, 2023|
|Estimated Study Completion Date :||May 1, 2023|
Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally (per os [PO]) daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage.
Patients will be randomized to receive Duloxetine or a placebo.
Placebo Comparator: Control
Patients randomized to the control arm will receive PO-matched placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing TKA at Rush University Medical Center.
Patients will be randomized to receive Duloxetine or a placebo.
- Cumulative opioid consumption at post op day 14 (POD14) [ Time Frame: Daily reporting of opioid consumption for 2 weeks following TKA ]Measuring in morphine equivalents, collect daily data on opioid consumption for each participant
- Patient reported outcome: Visual Analogue Scale (VAS) pain score [ Time Frame: At the 6 week postoperative mark, following TKA ]Using daily VAS pain score, scale of 1 to 10, 10 being the worst
- Patient reported outcome: Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS,JR) [ Time Frame: At the 6 week postoperative mark, following TKA ]KOOS,JR outcome assessed at 6 weeks post op from TKA. This is a 0-100 score where 100 represents a perfectly functioning joint.
- Patient reported outcome: Sleep duration and quality [ Time Frame: Daily reporting of sleep duration for 2 weeks following TKA ]Post-operative sleep duration and quality assessed daily, number of hours slept
- Complications [ Time Frame: Up to 3 months following surgery ]Adverse medication effects after initiating duloxetine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05086393
|Contact: Denis Nam, MD, MSc||(312)email@example.com|
|Contact: Anne DeBenedetti, BA||(312)firstname.lastname@example.org|
|United States, Illinois|
|Rush University medical Center||Recruiting|
|Chicago, Illinois, United States, 60612|
|Contact: Anne DeBenedetti, BA 312-432-2468 email@example.com|
|Sub-Investigator: Craig Della Valle, MD|
|Sub-Investigator: Vasili Karas, MD|